Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 196

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 196
---
 Lease requires the Company to pay certain taxes, insurance and operating costs relating to the leased premises. The Company has applied the short-term lease exception as the amendment is less than twelvemonths. The Lease is classified as an operating lease. Rent expense was $ 64,200for the year ended December 31, 2024 and $ 111,661for the year ended December 31, 2023. Future minimum lease payments under the operating lease as of December 31, 2024 is $ 10,700. F-12 REVELATION BIOSCIENCES, INC.
Notes to the Consolidated Financial Statements 4. Commitments and Contingencies(cont.) Commitments The Company enters into contracts in the normal course of business with third party service providers and vendors. These contracts generally provide for termination on notice and, therefore, are cancellable contracts and not considered contractual obligations and commitments. Contingencies From time to time, the Company may become subject to claims and litigation arising in the ordinary course of business. The Company is not a party to any material legal proceedings, nor is it aware of any material pending or threatened litigation. 5. 2023 Public Offering On February 13, 2023, the Company closed a public offering of 6,017shares of its common stock, 699pre-funded warrants to purchase shares of common stock with an exercise price of $ 0.048which did not have an expiration date (the “Class C Pre-Funded Warrants”) and 6,450,000warrants to purchase up to 13,438shares of common stock with an exercise price of $ 2,572.80which expire on February 14, 2028(the “Class C Common Stock Warrants”) at a combined offering price of $ 2,318.40per share of common stock and two Class C Common Stock Warrants, or $ 2,318.352per Class C Pre-Funded Warrant and two Class C Common Stock Warrants (the “February 2023 Public Offering”). Net cash proceeds to the Company from the offering were $ 14.0million and issuance costs were $ 1.5million. Roth Capital Partners, LLC (“Roth”) was engaged by the Company to act as its exclusive placement agent for the February 2023 Public Offering. The Company paid Roth a cash fee equal to 8.0% of the gross proceeds received by the Company in the public offering, totaling $ 1.2million